NEW YORK, Aug. 12, 2025 /PRNewswire/ -- Levi & Korsinsky, LLP notifies investors in Novo Nordisk A/S ("Novo" or the "Company") (NYSE: NVO) of a class action securities lawsuit. CLASS DEFINITION: The lawsuit seeks to recover losses on behalf of Novo investors who were adversely affected by alleged securities fraud between May 7, 2025 and July 28, 2025. Follow the link below to get more information and be contacted by a member of our team: https://zlk.com/pslra-1/novo-nordisk-a-s-lawsuit-submission-form-3?pri ...

Core Viewpoint - Novo Nordisk reported strong financial results for the first half of the year, driven by robust performance in the obesity treatment sector, despite a downward revision of revenue and operating profit expectations for 2025 due to anticipated market slowdowns and increased competition [4][8]. Financial Performance - For the first half of 2023, Novo Nordisk achieved sales of 154.9 billion Danish Krone (approximately 22.3 billion USD, 160.2 billion RMB), representing an 18% year-over-year growth at constant exchange rates [4]. - Operating profit reached 72.2 billion Danish Krone (approximately 10.4 billion USD, 74.7 billion RMB), marking a 29% increase compared to the previous year [4]. - The obesity treatment segment saw sales growth of 56%, significantly contributing to overall revenue [4]. Business Segment Analysis - The diabetes and obesity care division generated sales of 145.4 billion Danish Krone (approximately 21.5 billion USD), with an 18% year-over-year increase [4]. - Revenue from obesity drugs surged by 58% to 38.8 billion Danish Krone (approximately 5.7 billion USD) [4]. Product Performance - Sales of the diabetes drug Ozempic reached 64.5 billion Danish Krone (approximately 9.6 billion USD), a 15% increase year-over-year [6]. - Rybelsus, the oral formulation of semaglutide, generated sales of 11.3 billion Danish Krone (approximately 1.7 billion USD), reflecting a 5% growth [6]. - Wegovy, the weight loss injection, achieved sales of 36.9 billion Danish Krone (approximately 5.4 billion USD), with a remarkable 78% increase [6]. Market Position and Competition - Semaglutide's sales have surpassed that of the previously leading drug, Pembrolizumab (Keytruda), which recorded global sales of 15.2 billion USD in the first half of 2023, growing only 7% [8]. - The company has adjusted its 2025 revenue and profit forecasts due to anticipated slower growth in the U.S. obesity market and increased competition in the GLP-1 diabetes market [8]. Regulatory and Market Challenges - Despite the end of the FDA's grace period for large-scale compounding of drugs, illegal compounding practices continue, posing risks to patients [10]. - Novo Nordisk is taking legal action to protect patients from counterfeit semaglutide products and is advocating for stronger regulatory measures [10]. - The company's NovoCare pharmacy and telehealth initiatives are aimed at improving patient access, although current penetration rates are below expectations due to market expansion slowdowns and competition [10].

Core Insights - Enthusiasm for Novo Nordisk stock is increasing due to news from a competitor [1] - The company has reported quarterly financial results that have implications for shareholders [1] Financial Performance - Quarterly financial results were released, indicating potential impacts on shareholder value [1]

Core Viewpoint - The weight loss drug sector is experiencing a rebound driven by strong performance from Novo Nordisk and a technical correction after recent declines in stock prices [1][2]. Group 1: Market Performance - The weight loss drug concept sector opened higher on February 1, with notable gains from companies like Hongbo Pharmaceutical, Changshan Pharmaceutical, and Puli Pharmaceutical [1]. - The innovative drug ETF for the Shanghai-Hong Kong-Shenzhen market also saw a strong rebound, rising over 2%, with leading stocks including Kelaiying, WuXi Biologics, and others [1]. Group 2: Novo Nordisk's Performance - Novo Nordisk reported a 31% year-on-year increase in total revenue for 2023, with operating profit rising by 37% [1]. - The company's star product, semaglutide, generated sales of 145.81 billion Danish Krone (approximately 21.20 billion USD), marking an 88.78% increase and accounting for 62.78% of total revenue [1]. Group 3: Growth of GLP-1 Drugs - The semaglutide injection for weight management, Wegovy, achieved revenue of 31.34 billion Danish Krone (4.56 billion USD), reflecting a staggering 407% year-on-year growth [2]. - The global popularity of GLP-1 receptor agonists like semaglutide is attributed to their effectiveness in weight loss, blood sugar control, and cardiovascular benefits, leading to a surge in sales and clinical developments [2]. Group 4: Industry Innovations and Developments - Domestic companies are accelerating their innovation efforts in the weight loss drug market, with several GLP-1 receptor agonists in various stages of clinical trials [3]. - Companies like Hanyu Pharmaceutical and Changshan Pharmaceutical are actively pursuing new drug approvals and clinical trials for GLP-1 related products [3][4]. - The market for effective weight loss drugs remains vast due to the limited number of approved medications, highlighting significant growth potential in this sector [4].

Core Viewpoint - A class action securities lawsuit has been filed against Novo Nordisk A/S, alleging securities fraud that negatively impacted investors between May 7, 2025, and July 28, 2025 [1][2] Company Performance - The lawsuit claims that Novo Nordisk made misleading statements about its growth potential, particularly regarding the compounded GLP-1 market and the likelihood of patients switching to its branded products [2] - On July 29, 2025, Novo announced a reduction in its sales and profit outlook for the second half of 2025, attributing this to lower growth expectations for its products Wegovy and Ozempic, compounded GLP-1 usage, slower market expansion, and increased competition [2] - Following this announcement, Novo's stock price plummeted from $69.00 per share on July 28, 2025, to $53.94 per share on July 29, 2025, marking a decline of approximately 21.83% in one day [2] Legal Proceedings - Investors who suffered losses during the specified timeframe have until September 30, 2025, to request appointment as lead plaintiff in the lawsuit [3] - Class members may be entitled to compensation without any out-of-pocket costs or fees [3] Firm Background - Levi & Korsinsky, LLP has a strong track record in securities litigation, having secured hundreds of millions of dollars for shareholders over the past 20 years [4] - The firm has been recognized in ISS Securities Class Action Services' Top 50 Report for seven consecutive years as one of the leading securities litigation firms in the United States [4]

Core Insights - The global pharmaceutical sales ranking for the first half of 2025 has been released, highlighting the dominance of GLP-1 drugs in the market, with the top three drugs surpassing $10 billion in sales, driving industry growth [2][5] - The competition among pharmaceutical giants is intensifying, particularly in the GLP-1 category, with Novo Nordisk and Eli Lilly leading the charge [5][6] Group 1: GLP-1 Drug Market - GLP-1 drugs are the main drivers of market growth, contributing nearly 30% to the global biopharmaceutical market [3][5] - Semaglutide from Novo Nordisk topped the sales chart with $16.632 billion, while Eli Lilly's tirzepatide followed closely with $14.734 billion, marking a significant year-on-year growth of 121.3% [5][6] - The competitive landscape is shifting, with semaglutide's various formulations (injection, oral, and weight loss) ending Keytruda's long-standing dominance [5][6] Group 2: Emerging Therapies - New therapies such as bispecific antibodies, antibody-drug conjugates (ADC), and fusion proteins are gaining traction, accounting for over 15% of the top-selling drugs [3][10] - ADC drug Enhertu made its debut in the top rankings with $3.9 billion in sales, indicating a growing interest in innovative therapies [3][10] Group 3: CDK4/6 Inhibitors - The CDK4/6 inhibitor market is experiencing a reshuffle, with Eli Lilly's Abemaciclib leading at $2.648 billion, while Novartis' Ribociclib showed a remarkable growth rate of 58.7% [10] - Pfizer's Palbociclib, once a market leader, has seen a decline, dropping to $2.026 billion in sales [10] Group 4: BTK Inhibitors - The BTK inhibitor market is projected to reach approximately $12.5 billion by 2024, with Ibrutinib, Zebrutinib, and Acalabrutinib dominating the market [11][12] - Zebrutinib from BeiGene has entered the global top 50 list with $1.742 billion in sales, marking a significant achievement for Chinese innovation in the pharmaceutical sector [12][13]

Investment Strategy - The company employs a contrarian investment style, focusing on high-risk, illiquid options and shares [1] - The investment portfolio is split approximately 50%-50% between shares and call options, with a typical investment timeframe of 3-24 months [1] - The company targets stocks that have recently experienced sell-offs due to non-recurrent events, particularly when insiders are buying shares at lower prices [1] Analysis Methodology - Fundamental analysis is utilized to assess the health of companies, including their leverage and financial ratios compared to sector and industry averages [1] - Professional background checks are conducted on insiders who purchased shares after sell-offs to ensure credibility [1] - Technical analysis is employed to optimize entry and exit points, using multicolor lines for support and resistance levels on weekly charts [1]

Core Insights - The global pharmaceutical sales ranking for the first half of 2025 has been released, highlighting the dominance of GLP-1 drugs in the market, with the top three drugs surpassing $10 billion in sales, driving industry growth [1][6][13] - The competition among global pharmaceutical giants is intensifying, particularly in the metabolic drug sector, with companies like Novo Nordisk and Eli Lilly expected to expand their advantages [2][4] Group 1: GLP-1 Drug Market - GLP-1 drugs are leading the market, with Novo Nordisk's semaglutide family generating $16.632 billion in sales, marking its first position in the ranking [6] - Eli Lilly's tirzepatide follows closely with $14.734 billion in sales, showing a remarkable year-on-year growth of 121.3% [6] - The sales dynamics indicate that semaglutide's injection version holds a 61% market share, while the oral version accounts for 29% [6][7] Group 2: Emerging Therapies - New therapies such as bispecific antibodies, antibody-drug conjugates (ADC), and fusion proteins are gaining traction, accounting for over 15% of the market [1][13] - ADC drug Enhertu has entered the top rankings with $3.9 billion in sales [1] - mRNA vaccines have collectively contributed $9.4 billion, showcasing the impact of innovative therapies in the pharmaceutical landscape [1] Group 3: CDK4/6 Inhibitors - The CDK4/6 inhibitor market is experiencing a reshuffle, with Eli Lilly's Abemaciclib leading at $2.648 billion, while Novartis's Ribociclib has surged with a 58.7% growth [10][11] - Pfizer's Palbociclib has seen a decline, dropping to $2.026 billion, marking a significant shift in market dynamics [11] Group 4: Chinese Pharmaceutical Innovations - The entry of Chinese innovation, specifically BeiGene's Zebrutinib, into the global top 50 with $1.742 billion in sales signifies a breakthrough for domestic drugs [12] - Zebrutinib's success reflects the potential for Chinese pharmaceuticals to transition from thematic investments to performance-driven investments in the global market [12]

Core Insights - The global obesity market is primarily dominated by Eli Lilly (LLY) and Novo Nordisk (NVO), with LLY's Zepbound and NVO's Wegovy as leading GLP-1 injectable therapies. Zepbound has shown rapid sales growth, surpassing Wegovy in weight-loss efficacy in clinical studies [1][3] - In the first half of 2025, Zepbound generated $5.69 billion in revenues, prompting LLY to raise its full-year sales guidance to $60-$62 billion. In contrast, Wegovy recorded $5.41 billion in sales during the same period, leading Novo Nordisk to revise its sales outlook downward due to increased competition [2][8] - LLY faced a setback with its oral GLP-1 candidate, orforglipron, which did not meet investor expectations in weight-loss efficacy, resulting in an 18.6% decline in LLY shares. This has shifted market confidence towards Novo Nordisk, which saw a 4.7% increase in its stock [3][4] Company Performance - LLY's stock has underperformed, losing 19% year-to-date compared to an 8.3% decline in the industry. The stock is trading at a price/earnings ratio of 22.85, higher than the industry average of 13.71, but below its five-year mean of 34.54 [7][11] - Estimates for LLY's 2025 earnings have improved from $21.92 to $22.11 per share, while estimates for 2026 earnings have slightly declined from $30.84 to $30.74 [16] Market Developments - The setback with orforglipron has shifted focus towards oral obesity treatment options, which could enhance patient adherence. Novo Nordisk is seeking FDA approval for a 25 mg oral semaglutide, with a decision expected by year-end [5][8] - Other companies, such as Viking Therapeutics, are also advancing in the development of GLP-1-based obesity treatments, with ongoing studies for their investigational drug VK2735 [6]

Analyst's Disclosure:I/we have no stock, option or similar derivative position in any of the companies mentioned, but may initiate a beneficial Long position through a purchase of the stock, or the purchase of call options or similar derivatives in NOVO over the next 72 hours. I wrote this article myself, and it expresses my own opinions. I am not receiving compensation for it (other than from Seeking Alpha). I have no business relationship with any company whose stock is mentioned in this article. Seeking ...